{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 1 - 10 of 10 results
Status:
US Approved Rx
(2000)
First approved in 1997
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02503202: Phase 3 Interventional Completed Prevention of Ebola Infection
(2015)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT03192371: Phase 4 Interventional Withdrawn Virus Diseases
(2018)
Source URL:
First approved in 1997
Source:
BLA103334
Source URL:
Class:
STRUCTURALLY DIVERSE